Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 6, 2021Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 6, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug...
-
Apr 29, 2021
Eisai announced today that the European Journal of Cancer published the results from a post hoc analysis of the Phase 3 SELECT study evaluating the impact of lung metastases on overall survival...
Mar 31, 2021Endometrial Cancer Is on the Rise, Yet Under-Recognized. Black Health Matters, FORCE, SHARE and Eisai Partner to Inspire Women to Listen, Advocate and Put Their Health FirstEisai Inc. announced today the launch of Spot Her—an initiative to end the silence around endometrial cancer, a type of uterine cancer, and inspire women to listen, advocate and put their health...
-
Mar 19, 2021
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., March 19, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced the first presentation of...
-
Mar 10, 2021Pivotal Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Chemotherapy in Patients with Advanced Endometrial Cancer to be Presented During Plenary Session
Eisai will present two abstracts at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer, March 19-25 (#SGOMtg). These investigational data include the first...